BTK and autoimmune disease: Noncovalent BTK inhibitors such as pirtobrutinib (LOXO-305), MK-1026 (ARQ-531), fenebrutinib (GDC-0853), and vecabrutinib (SNS-062) also look promising in oncology clinical trials (139) and may similarly be candidates for treating autoimmune diseases.